HCC1954Homo sapiens (Human)Cancer cell line

Also known as: Hamon Cancer Center 1954, HCC-1954

🤖 AI SummaryBased on 11 publications

Quick Overview

Human breast cancer cell line with known genetic alterations and drug sensitivity profiles.

Detailed Summary

HCC1954 is a human breast cancer cell line derived from a patient with breast carcinoma. It is widely used in cancer research for studying molecular mechanisms, drug response, and therapeutic target identification. The cell line exhibits specific genetic features, including mutations and copy number variations, which contribute to its unique biological properties. Research on HCC1954 has provided insights into the molecular pathways involved in breast cancer progression and has been instrumental in evaluating the efficacy of various therapeutic agents. Its characterization in multiple studies highlights its relevance in understanding tumor heterogeneity and developing targeted therapies.

Research Applications

Cancer biology researchDrug sensitivity profilingMolecular mechanism studiesTherapeutic target identification

Key Characteristics

Genetic alterationsDrug response profilesTumor heterogeneity studies
Generated on 6/16/2025

Basic Information

Database IDCVCL_1259
SpeciesHomo sapiens (Human)
Tissue SourceBreast[UBERON:UBERON_0000310]

Donor Information

Age61
Age CategoryAdult
SexFemale
Raceeast_indian
Subtype Featuresbasal_A HER2+

Disease Information

DiseaseBreast ductal carcinoma
LineageBreast
SubtypeBreast Ductal Carcinoma In Situ
OncoTree CodeDCIS

DepMap Information

Source TypeATCC
Source IDACH-000859_source

Known Sequence Variations

TypeGene/ProteinDescriptionZygosityNoteSource
MutationSimpleTP53p.Tyr163Cys (c.488A>G)Unspecified-PubMed=12884349
MutationSimplePIK3CAp.His1047Arg (c.3140A>G)Unspecified-PubMed=25926053, PubMed=20570890
Gene fusionCLTCCLTC-VMP1--from parent cell line HCC1954

Haplotype Information (STR Profile)

Short Tandem Repeat (STR) profile for cell line authentication.

Amelogenin
X
CSF1PO
10
D10S1248
14,15
D12S391
22
D13S317
8,9
D16S539
9,11
D18S51
14,18
D19S433
13,15.2
D1S1656
15,16
D21S11
28,32.2
D22S1045
11,15
D2S1338
17,26
D2S441
10,11
D3S1358
15,16
D5S818
11
D7S820
10,11
D8S1179
12,15
FGA
22,23
Penta D
9,12
Penta E
12,16
TH01
6,7
TPOX
8,9
vWA
18,19
Gene Expression Profile
Gene expression levels and statistical distribution
Loading cohorts...
Full DepMap dataset with combined data across cell lines

Loading gene expression data...

Publications

Pan-cancer proteomic map of 949 human cell lines.";

Robinson P.J., Zhong Q., Garnett M.J., Reddel R.R.

Cancer Cell 40:835-849.e8(2022).

Quantitative proteomics of the Cancer Cell Line Encyclopedia.";

Sellers W.R., Gygi S.P.

Cell 180:387-402.e16(2020).

Next-generation characterization of the Cancer Cell Line Encyclopedia.

Sellers W.R.

Nature 569:503-508(2019).

Prioritization of cancer therapeutic targets using CRISPR-Cas9 screens.

Stronach E.A., Saez-Rodriguez J., Yusa K., Garnett M.J.

Nature 568:511-516(2019).

An interactive resource to probe genetic diversity and estimated ancestry in cancer cell lines.

Dutil J., Chen Z.-H., Monteiro A.N.A., Teer J.K., Eschrich S.A.

Cancer Res. 79:1263-1273(2019).

Enhancer transcription reveals subtype-specific gene expression programs controlling breast cancer pathogenesis.

Bedford M.T., Shi X.-B., Li W., Barton M.C., Dent S.Y.R., Kraus W.L.

Genome Res. 28:159-170(2018).

Multidimensional phenotyping of breast cancer cell lines to guide preclinical research.

Lakhani S.R.

Breast Cancer Res. Treat. 167:289-301(2018).

Glycoproteins in claudin-low breast cancer cell lines have a unique expression profile.

Yen T.-Y., Bowen S., Yen R., Piryatinska A., Macher B.A., Timpe L.C.

J. Proteome Res. 16:1391-1400(2017).

Characterization of human cancer cell lines by reverse-phase protein arrays.

Liang H.

Cancer Cell 31:225-239(2017).

A landscape of pharmacogenomic interactions in cancer.";

Wessels L.F.A., Saez-Rodriguez J., McDermott U., Garnett M.J.

Cell 166:740-754(2016).

TCLP: an online cancer cell line catalogue integrating HLA type, predicted neo-epitopes, virus and gene expression.

Loewer M., Sahin U., Castle J.C.

Genome Med. 7:118.1-118.7(2015).

Parallel genome-scale loss of function screens in 216 cancer cell lines for the identification of context-specific genetic dependencies.

Golub T.R., Root D.E., Hahn W.C.

Sci. Data 1:140035-140035(2014).

A catalog of HLA type, HLA expression, and neo-epitope candidates in human cancer cell lines.

Boegel S., Lower M., Bukur T., Sahin U., Castle J.C.

OncoImmunology 3:e954893.1-e954893.12(2014).

A resource for cell line authentication, annotation and quality control.

Neve R.M.

Nature 520:307-311(2015).

A comprehensive transcriptional portrait of human cancer cell lines.

Settleman J., Seshagiri S., Zhang Z.-M.

Nat. Biotechnol. 33:306-312(2015).

Modeling precision treatment of breast cancer.";

Collisson E.A., van 't Veer L.J., Spellman P.T., Gray J.W.

Genome Biol. 14:R110.1-R110.14(2013).

Characterization of cell lines derived from breast cancers and normal mammary tissues for the study of the intrinsic molecular subtypes.

Harrell J.C., Roman E., Adamo B., Troester M.A., Perou C.M.

Breast Cancer Res. Treat. 142:237-255(2013).

Glutamine sensitivity analysis identifies the xCT antiporter as a common triple-negative breast tumor therapeutic target.

McCormick F., Gray J.W.

Cancer Cell 24:450-465(2013).

Breakpoint analysis of transcriptional and genomic profiles uncovers novel gene fusions spanning multiple human cancer types.

West R.B., Pollack J.R.

PLoS Genet. 9:E1003464-E1003464(2013).

miRNA expression profiling of 51 human breast cancer cell lines reveals subtype and driver mutation-specific miRNAs.

Martens J.W.M.

Breast Cancer Res. 15:R33.1-R33.17(2013).

Molecular characterisation of cell line models for triple-negative breast cancers.

Reis-Filho J.S., Tutt A.

BMC Genomics 13:619.1-619.14(2012).

Essential gene profiles in breast, pancreatic, and ovarian cancer cells.

Rottapel R., Neel B.G., Moffat J.

Cancer Discov. 2:172-189(2012).

The Cancer Cell Line Encyclopedia enables predictive modelling of anticancer drug sensitivity.

Morrissey M.P., Sellers W.R., Schlegel R., Garraway L.A.

Nature 483:603-607(2012).

Reassessment of estrogen receptor expression in human breast cancer cell lines.

Ford C.H.J., Al-Bader M., Al-Ayadhi B., Francis I.

Anticancer Res. 31:521-527(2011).

A genome-wide screen for microdeletions reveals disruption of polarity complex genes in diverse human cancers.

Haber D.A.

Cancer Res. 70:2158-2164(2010).

Signatures of mutation and selection in the cancer genome.";

Deloukas P., Yang F.-T., Campbell P.J., Futreal P.A., Stratton M.R.

Nature 463:893-898(2010).

Breast cancer cell lines carry cell line-specific genomic alterations that are distinct from aberrations in breast cancer tissues: comparison of the CGH profiles between cancer cell lines and primary cancer tissues.

Yamamoto S., Oka M., Hirano T., Sasaki K.

BMC Cancer 10:15.1-15.10(2010).

Molecular profiling of breast cancer cell lines defines relevant tumor models and provides a resource for cancer gene discovery.

Pollack J.R.

PLoS ONE 4:E6146-E6146(2009).

The genomic landscapes of human breast and colorectal cancers.";

Vogelstein B.

Science 318:1108-1113(2007).

A collection of breast cancer cell lines for the study of functionally distinct cancer subtypes.

Johnson M.D., Lippman M.E., Ethier S.P., Gazdar A.F., Gray J.W.

Cancer Cell 10:515-527(2006).

The consensus coding sequences of human breast and colorectal cancers.

Vogelstein B., Kinzler K.W., Velculescu V.E.

Science 314:268-274(2006).

Searching for microsatellite mutations in coding regions in lung, breast, ovarian and colorectal cancers.

Minna J.D.

Oncogene 20:1005-1009(2001).

Characterization of paired tumor and non-tumor cell lines established from patients with breast cancer.

Tomlinson G.E., Tonk V., Ashfaq R., Leitch A.M., Minna J.D., Shay J.W.

Int. J. Cancer 78:766-774(1998).